All In Biotech

Drug Trial Radar · NCT07773532

Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

Predictive Capacity of Baseline Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index for Mirabegron Treatment Response in Women With Overactive Bladder: A Prospective Cohort Study

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Nov 2, 2027

Study completion Nov 2, 2027

Sponsor

Lead sponsor
Bagcilar Training and Research HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.

Conditions

  • Overactive Bladder (OAB)

Interventions

  • Mirabegron (beta3-adrenoceptor agonist)Drug

    Mirabegron 50 mg orally once daily, initiated and managed by the treating physician as part of routine clinical care. The drug is not assigned by the study protocol; the study observes patients in whom this treatment has been started within standard practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Discriminative ability of baseline neutrophil-to-lymphocyte ratio for mirabegron treatment responseTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bagcilar Training and Research Hospital

    Istanbul, Bagcilar, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.